Investigational drug · Phase 3
CTX-009
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
6
Any phase or sponsor naming "CTX-009"
First trial start
2022
Dec 8, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CTX-009", any sponsor or status.
Conditions studied
As listed on its trial records.
- Biliary Tract Cancer
- Cholangiocarcinoma
- Gall Bladder Cancer
- Ampullary Cancer
- Metastatic Colorectal Cancer
- Colon Cancer
- Rectal Cancer
Approved drugs for the same conditions: Colorectal cancer · Bladder and urothelial cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "CTX-009" as an intervention, largest first.
- A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)Pivotal-lookingActive, not recruiting
Compass TherapeuticsIndustry
NCT05506943 · 168 participants · Start Jan 9, 2023 · Primary completion Aug 31, 2027
Drug: CTX-009; Paclitaxel · For: Biliary Tract Cancer; Cholangiocarcinoma; Gall Bladder Cancer and 1 more
Sites: Phoenix, Arizona; Tucson, Arizona; Los Angeles, California · 34 sites in all
Washington University School of MedicineAcademic, hospital or other
NCT07392957 · 54 participants (planned) · Start Jun 16, 2026 · Primary completion Jun 30, 2029
Drug: CTX-009; CTX-471 · For: Glioblastoma
Sites: St Louis, Missouri
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06548412 · 50 participants (planned) · Start Jan 22, 2025 · Primary completion May 1, 2027
Drug: Gemcitabine; Cisplatin and 2 more · For: Metastatic Biliary Tract Cancer
Sites: Houston, Texas
Compass TherapeuticsIndustry
NCT05513742 · 49 participants · Start Dec 8, 2022 · Primary completion May 15, 2025
Drug: CTX-009 · For: Metastatic Colorectal Cancer; Colon Cancer; Rectal Cancer
Sites: Hot Springs, Arkansas; Fort Myers, Florida; St. Petersburg, Florida · 7 sites in all
Handok Inc.Industry
NCT04492033 · 41 participants · Start Jun 22, 2020 · Primary completion Jan 8, 2024
Drug: CTX-009 (ABL001); Paclitaxel and 1 more · For: P1b: Advanced Solid Tumors; P2: Biliary Tract Cancer
Sites: Seongnam-si, South Korea; Seoul, South Korea · 4 sites in all
- Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal CancerNot yet recruiting
Washington University School of MedicineAcademic, hospital or other
NCT07662031 · 25 participants (planned) · Start Dec 31, 2026 · Primary completion Dec 31, 2030
Drug: Tovecimig; Irinotecan and 2 more · For: Colorectal Cancer; Metastatic Colorectal Cancer
Sites: St Louis, Missouri
Newest research
PubMed records naming it or its code names, newest first.
- Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor.
Na JY, Jeon J, Huh KY, et al. · Cancer Sci 2024
- COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC.
Azad N, Hu Z, Sahin I, et al. · Future Oncol 2024
Also in development for Biliary Tract Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.